Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05434598 · ClinicalTrials.gov registry record · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
A NA study of Myelodysplastic Syndromes and Whole Genome Sequencing, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05434598: Recruiting NA study of Myelodysplastic Syndromes and Whole Genome Sequencing, sponsored by Washington University School of Medicine.
NCT05434598 is a NA study of Myelodysplastic Syndromes and Whole Genome Sequencing that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 60 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05434598, a NA study of Myelodysplastic Syndromes and Whole Genome Sequencing, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Primary Outcome
-The number of recurrent structural variants detected by ChromoSeq will be compared to those detected by conventional cytogenetics using two non-inferiority tests for dependent samples using non-inferiority margin of 1%.
Conditions Studied
Interventions
- DEVICE ChromoSeq
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT05434598 shows while recruiting
NCT05434598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which ChromoSeq is the first listed.
NCT05434598 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05434598 about?
NCT05434598 is a clinical study titled "Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS". This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pati...
What is the current status of trial NCT05434598?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2022-07-27. Estimated completion is 2027-08-31.
What conditions does trial NCT05434598 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Whole Genome Sequencing.
What interventions are being tested in trial NCT05434598?
The interventions under investigation include: ChromoSeq (DEVICE).
Who is sponsoring clinical trial NCT05434598?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05434598 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05434598's enrollment target sits among peer trials
60 75th of 173 higher than 96 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Home Blood Transfusions
RECRUITING · NA
-
Mosaic Trial for Stem Cell Transplant Recipients
RECRUITING · NA
-
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI